Vasculitis and Giant Cell Arteritis News

In this episode, I interview the NIH team who brought you VEXAS! Hear different points of view, how it was discovered, clinical presentations as well as where this research could lead. Then, Dr. Kastner provides his historical take on autoinflammatory disorders!

Maternal ankylosing spondylitis is associated with a 2.02-times higher likelihood of Kawasaki disease in the offspring, according to a research letter published in JAMA Network Open.

Experimental studies indicate that sleep loss can lead to elevated concentrations of proinflammatory cytokines and enhance the perception of pain among patients with immune-mediated inflammatory diseases, according to a speaker here.

Despite an ever-growing array of therapeutic options, patients with antineutrophil cytoplasmic antibody-associated vasculitis often fail to achieve remission, according to a speaker at the ACR State-of-the-Art Clinical Symposium.

Clinicians and researchers continue to debate the etiology and treatment paradigms for the severe inflammatory syndrome that impacts some children with COVID-19, according to a speaker at the ACR State-of-the-Art Clinical Symposium.

Tocilizumab improves outcomes in patients with giant cell arteritis who present with polymyalgia rheumatica symptoms only, cranial symptoms only or both at baseline, according to data published in Seminars in Arthritis & Rheumatism.

Darker skin tones are “significantly underrepresented” in rheumatology clinical image banks, including the American College of Rheumatology Image Library and The New England Journal of Medicine Images in Clinical Medicine, according to data.

Rituximab was associated with more severe COVID-19 in patients with inflammatory rheumatic and musculoskeletal diseases, according to data published in The Lancet Rheumatology.

Despite COVID-19 quarantine measures, Kawasaki disease incidence was unchanged in Japan compared with significant declines in respiratory tract and gastrointestinal infections, indicating airborne rather than contact or droplet transmission.

The incidence of scleritis declined by about a third in the United Kingdom between 1997 and 2018, according to data published in Arthritis & Rheumatology.